Highmark Interactive Announces Partnership with PointClickCare, Integrating Game-Based Testing for Seniors’ Brain Health
July 30, 2020 09:22 ET
|
Highmark Interactive
TORONTO, July 30, 2020 (GLOBE NEWSWIRE) -- Highmark Interactive, creators of the world’s first mobile, gamified, FDA cleared neurological assessment tool, is proud to announce its partnership with...
Annovis Bio CEO to Present the Company’s Novel Approach to Treating Parkinson’s Disease at University of Pennsylvania
July 20, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Receives Institutional Review Board Approval to Initiate 15 Site Phase 2 Study in 68 Parkinson’s and Alzheimer’s Patients
July 07, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., July 07, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Cutting Edge medical advancements in technology - MoviWearMed is geared to protect the most vulnerable population during Covid-19
June 19, 2020 08:00 ET
|
MoviWear
TORONTO, June 19, 2020 (GLOBE NEWSWIRE) -- Jacob Moshinsky, founder of MoviWear has once again created buzz, this time in the medical industry. MoviWearMed is a new medical platform that allows 24/7...
Annovis Bio Announces Positive Results from NIH Funded Chronic Toxicology Study
June 16, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Issued European Patent for Method of Treating Alzheimer’s Disease with ANVS401
June 02, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Ault Life Sciences Launches $100 Million 506(c) and Regulation S Offering
May 07, 2020 07:00 ET
|
Ault Life Sciences, Inc.
NEWPORT BEACH, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- Ault Life Sciences, Inc. (“ALSI” or the “Company”), a Delaware corporation, announced that it is seeking to raise up to $100 million through...
Ault Life Sciences™ Presents the Todd Ault #KOalz Podcast Interview with Dr. Thomas Wisniewski
May 01, 2020 09:00 ET
|
Ault Life Sciences, Inc.
NEWPORT BEACH, Cal., May 01, 2020 (GLOBE NEWSWIRE) -- Ault Life Sciences™, Inc. (“ALSI” or the “Company”), a Delaware corporation, invites everyone interested in Alzheimer’s disease to watch an...
Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients
April 30, 2020 06:45 ET
|
Annovis Bio Inc.
BERWYN, Pa., April 30, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies
April 23, 2020 07:00 ET
|
Annovis Bio Inc.
BERWYN, Pa., April 23, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease, Parkinson’s disease and other...